TY - BOOK AU - Loorand-Stiver, L. PY - 2013 DA - 2013// TI - Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives [environmental scan, issue 42] PB - Canadian Agency for Drugs and Technologies in. Health CY - Ottawa ID - Loorand-Stiver2013 ER - TY - STD TI - BIOTECanada. The Canadian rare disease therapies landscape: Bridging opportunity to reality. http://www.biotech.ca/wp-content/uploads/2016/03/white_paper_mar_2.pdf. Accessed 20 Dec 2017. UR - http://www.biotech.ca/wp-content/uploads/2016/03/white_paper_mar_2.pdf ID - ref2 ER - TY - STD TI - Canadian Institute of Health Research. New emerging team for rare diseases. http://rare-diseases.ca/. Accessed 20 Dec 2017. UR - http://rare-diseases.ca/ ID - ref3 ER - TY - JOUR AU - Hughes, D. A. AU - Tunnage, B. AU - Yeo, S. T. PY - 2005 DA - 2005// TI - Drugs for exceptionally rare diseases: do they deserve special status for funding? JO - QJM VL - 98 UR - https://doi.org/10.1093/qjmed/hci128 DO - 10.1093/qjmed/hci128 ID - Hughes2005 ER - TY - JOUR AU - Drummond, M. F. AU - Kanavos, P. AU - Ubel, P. AU - Rovira, J. PY - 2007 DA - 2007// TI - Assessing the economic challenges posed by orphan drugs JO - Int J Technol Assess Health Care VL - 23 UR - https://doi.org/10.1017/S0266462307051550 DO - 10.1017/S0266462307051550 ID - Drummond2007 ER - TY - JOUR AU - Clarke, J. T. R. PY - 2006 DA - 2006// TI - Is the current approach to reviewing new drugs condemning the victims of rare disease to death? A call for a national orphan drug review policy JO - Can Med Assoc J VL - 174 UR - https://doi.org/10.1503/cmaj.050706 DO - 10.1503/cmaj.050706 ID - Clarke2006 ER - TY - JOUR AU - Blankart, C. R. AU - Stargardt, T. AU - Schreyogg, J. PY - 2011 DA - 2011// TI - Availability of and access to orphan drugs. An international comparison of pharmaceutical treatments for pulmonary arterial hypertension, fabry disease, hereditary angiodema and chronic myeloid leukemia JO - PharmacoEconomics VL - 29 UR - https://doi.org/10.2165/11539190-000000000-00000 DO - 10.2165/11539190-000000000-00000 ID - Blankart2011 ER - TY - JOUR AU - Vegter, S. AU - Rozenbaum, M. H. AU - Postema, R. AU - Tolley, K. AU - Postma, M. J. PY - 2010 DA - 2010// TI - Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations JO - Clin Ther VL - 32 UR - https://doi.org/10.1016/j.clinthera.2010.08.006 DO - 10.1016/j.clinthera.2010.08.006 ID - Vegter2010 ER - TY - JOUR AU - Denis, A. AU - Mergaert, L. AU - Fostier, C. AU - Cleemput, I. AU - Hulstaert, F. AU - Simoens, S. PY - 2011 DA - 2011// TI - Critical assessment of Belgian reimbursement dossiers of orphan drugs JO - PharmacoEconomics VL - 29 UR - https://doi.org/10.2165/11585980-000000000-00000 DO - 10.2165/11585980-000000000-00000 ID - Denis2011 ER - TY - JOUR AU - Cote, A. AU - Keating, B. PY - 2012 DA - 2012// TI - What is wrong with orphan drug policies? JO - Value Health VL - 15 UR - https://doi.org/10.1016/j.jval.2012.09.004 DO - 10.1016/j.jval.2012.09.004 ID - Cote2012 ER - TY - JOUR AU - Simoens, S. PY - 2011 DA - 2011// TI - Pricing and reimbursement of orphan drugs: the need for more transparency JO - Orphanet J Rare Dis VL - 6 UR - https://doi.org/10.1186/1750-1172-6-42 DO - 10.1186/1750-1172-6-42 ID - Simoens2011 ER - TY - JOUR AU - Panju, A. H. AU - Bell, C. M. PY - 2010 DA - 2010// TI - Policy alternatives for treatments for rare diseases JO - Can Med Assoc J VL - 182 UR - https://doi.org/10.1503/cmaj.081429 DO - 10.1503/cmaj.081429 ID - Panju2010 ER - TY - STD TI - House of Commons Debates. April 14, 2008; Treatment of rare disorders. http://www.parl.gc.ca/HousePublications/Publication.aspx?DocId=3419095&Language=E&Mode=1. Accessed 21 Dec 2017. UR - http://www.parl.gc.ca/HousePublications/Publication.aspx?DocId=3419095&Language=E&Mode=1 ID - ref13 ER - TY - JOUR AU - Lee, D. K. AU - Wong, B. PY - 2014 DA - 2014// TI - An orphan drug framework (ODF) for Canada JO - J Popul Ther Clin Pharmacol VL - 21 ID - Lee2014 ER - TY - JOUR AU - Wong-Rieger, D. PY - 2013 DA - 2013// TI - Canada's long journey toward an orphan drug framework JO - Advocate VL - 20 ID - Wong-Rieger2013 ER - TY - STD TI - Benefits Canada. Health Canada puts the brakes on plan for orphan drug framework: http://www.benefitscanada.com/news/health-canada-puts-brakes-on-plan-for-orphan-drug-framework-105588. Accessed 7 Dec 2017. UR - http://www.benefitscanada.com/news/health-canada-puts-brakes-on-plan-for-orphan-drug-framework-105588 ID - ref16 ER - TY - JOUR AU - Tierney, M. AU - Manns, B. PY - 2008 DA - 2008// TI - Optimizing the use of prescription drugs in Canada through the Common Drug Review JO - Can Med Assoc J VL - 178 UR - https://doi.org/10.1503/cmaj.070713 DO - 10.1503/cmaj.070713 ID - Tierney2008 ER - TY - STD TI - Canadian Agency for Drugs and Technologies in Health. Procedure for CADTH Common Drug Review. https://www.cadth.ca/media/cdr/process/CDR_Procedure.pdf. Accessed 21 Dec 2017. UR - https://www.cadth.ca/media/cdr/process/CDR_Procedure.pdf ID - ref18 ER - TY - JOUR AU - Rocchi, A. AU - Miller, E. AU - Hopkins, R. B. AU - Goeree, R. PY - 2012 DA - 2012// TI - Common drug review recommendations. An evidence base for expectations JO - PharmacoEconomics VL - 30 UR - https://doi.org/10.2165/11593030-000000000-00000 DO - 10.2165/11593030-000000000-00000 ID - Rocchi2012 ER - TY - JOUR AU - Husereau, D. AU - Dempster, W. AU - Blanchard, A. AU - Chambers, J. PY - 2014 DA - 2014// TI - Evolution of drug reimbursement in Canada: the pan-Canadian Pharmaceutical Alliance for new drugs JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.08.2673 DO - 10.1016/j.jval.2014.08.2673 ID - Husereau2014 ER - TY - STD TI - Pan-Canadian Oncology Drug Review. https://www.cadth.ca/about-cadth/what-we-do/products-services/pcodr. Accessed 21 Dec 2017. UR - https://www.cadth.ca/about-cadth/what-we-do/products-services/pcodr ID - ref21 ER - TY - STD TI - The Rx&D International Report on access to medicines 2010–2011. http://www.wyatthealth.com/wp-content/uploads/IRAM/iram-2010-2011-English.pdf. Accessed 21 Dec 2017. UR - http://www.wyatthealth.com/wp-content/uploads/IRAM/iram-2010-2011-English.pdf ID - ref22 ER - TY - JOUR AU - Clement, F. M. AU - Harris, A. AU - Li, J. J. AU - Yong, K. AU - Lee, K. M. AU - Manns, B. J. PY - 2009 DA - 2009// TI - Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia and Canada JO - JAMA VL - 302 UR - https://doi.org/10.1001/jama.2009.1409 DO - 10.1001/jama.2009.1409 ID - Clement2009 ER - TY - STD TI - Standing Committee on Health. Prescription drugs-Part 1. The Common Drug Review: An F/P/T process. http://www.parl.gc.ca/content/hoc/Committee/392/HESA/Reports/RP3162492/hesarp02/hesarp02-e.pdf. Accessed 21 Dec 2017. UR - http://www.parl.gc.ca/content/hoc/Committee/392/HESA/Reports/RP3162492/hesarp02/hesarp02-e.pdf ID - ref24 ER - TY - STD TI - Recommendation framework for CADTH Common Drug Review and pan-Canadian Oncology Drug Review programs: Guidance for CADTH’s Drug Expert Committee. March 2016. https://www.cadth.ca/media/cdr/templates/pre-sub-phase/CDR_pCODR_recommendations_framework.pdf. Accessed: 21 Dec 2017. UR - https://www.cadth.ca/media/cdr/templates/pre-sub-phase/CDR_pCODR_recommendations_framework.pdf ID - ref25 ER - TY - STD TI - Tadros N, McCormick J. Towards a new way of evaluating orphan drugs at CADTH. http://www.orphan-drugs.org/2017/02/23/towards-new-way-evaluating-orphan-drugs-cadth/. Accessed 21 Dec 2017. UR - http://www.orphan-drugs.org/2017/02/23/towards-new-way-evaluating-orphan-drugs-cadth/ ID - ref26 ER - TY - STD TI - Orphanet: Orphan drug list. http://www.orpha.net/consor/cgi-bin/Drugs_ListDrugs_List.php?lng=EN&TAG=A. Accessed 21 Dec 2017. UR - http://www.orpha.net/consor/cgi-bin/Drugs_ListDrugs_List.php?lng=EN&TAG=A ID - ref27 ER - TY - STD TI - Food and Drug Administration. Orphan Drug List. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed 21 Dec 2017. UR - http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm ID - ref28 ER - TY - STD TI - CADTH Common Drug Review (CDR) Reports. https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/reports. Accessed 21 Dec 2017. UR - https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/reports ID - ref29 ER - TY - STD TI - Scottish Medicines Consortium. http://www.scottishmedicines.org.uk/. Accessed 21 Dec 2017. UR - http://www.scottishmedicines.org.uk/ ID - ref30 ER - TY - STD TI - Scottish Medicines Consortium. PACE: Medicines for end of life and very rare conditions. http://www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/PACE. Accessed 21 Dec 2017. UR - http://www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/PACE ID - ref31 ER - TY - STD TI - Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. http://www.pbac.pbs.gov.au/. Accessed 21 Dec 2017. UR - http://www.pbac.pbs.gov.au/ ID - ref32 ER - TY - STD TI - Life Savings Drug Program Criteria and Conditions. http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-criteria. Accessed 21 Dec 2017. UR - http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-criteria ID - ref33 ER - TY - STD TI - PBAC Guidelines. F.3 Other relevant factors. https://pbac.pbs.gov.au/content/information/archived-versions/pbac-guidelines-v4-5.pdf. Accessed July 2015. UR - https://pbac.pbs.gov.au/content/information/archived-versions/pbac-guidelines-v4-5.pdf ID - ref34 ER - TY - JOUR AU - Rosenberg-Yunger, Z. R. S. AU - Daar, A. S. AU - Thorsteinsdottir, H. AU - Martin, K. M. PY - 2011 DA - 2011// TI - Priority setting for orphan drugs: an international comparison JO - Health Policy VL - 100 UR - https://doi.org/10.1016/j.healthpol.2010.09.008 DO - 10.1016/j.healthpol.2010.09.008 ID - Rosenberg-Yunger2011 ER - TY - STD TI - PHARMAC. Pharmaceutical Management Agency: https://www.pharmac.govt.nz/. Accessed 21 Dec 2017. UR - https://www.pharmac.govt.nz ID - ref36 ER - TY - JOUR AU - Wonder, M. AU - Milne, R. PY - 2011 DA - 2011// TI - Access to new medicines in New Zealand compared to Australia JO - N Z Med J VL - 124 ID - Wonder2011 ER - TY - STD TI - PHARMAC. High cost medicines for rare diseases. Discussion document and a request for your input. http://www.pharmac.health.nz/assets/high-cost-medicines-discussion-document-2014-04.pdf. Accessed 21 Dec 2017. UR - http://www.pharmac.health.nz/assets/high-cost-medicines-discussion-document-2014-04.pdf ID - ref38 ER - TY - STD TI - PHARMAC’s Decision Criteria. Proposal for change. February 2014. http://www.pharmac.health.nz/assets/consultation-2014-02-19-dcc.pdf. Accessed 21 Dec 2017. UR - http://www.pharmac.health.nz/assets/consultation-2014-02-19-dcc.pdf ID - ref39 ER - TY - STD TI - PHARMAC. Medicines for rare disorders: http://www.pharmac.govt.nz/medicines/how-medicines-are-funded/medicines-for-rare-disorders/. Accessed 21 Dec 2017. UR - http://www.pharmac.govt.nz/medicines/how-medicines-are-funded/medicines-for-rare-disorders/ ID - ref40 ER - TY - STD TI - Institut national d’excellence en santé et en services sociaux (INESSS). https://www.inesss.qc.ca/en.html. Accessed 21 Dec 2017. UR - https://www.inesss.qc.ca/en.html ID - ref41 ER - TY - JOUR PY - 2011 DA - 2011// TI - Prise en charge des maladies rares : Expériences étrangères. Rapport préparé par Stéphanie Elger JO - ETMIS VL - 7 ID - ref42 ER - TY - STD TI - Scottish Medicines Consortium. SMC Advice Directory: http://www.scottishmedicines.org.uk/SMC_Advice/Advice_Directory/SMC_Advice_Directory. Accessed 21 Dec 2017. UR - http://www.scottishmedicines.org.uk/SMC_Advice/Advice_Directory/SMC_Advice_Directory ID - ref43 ER - TY - STD TI - Australian Government. Department of Health. Public summary documents by product. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/public-summary-documents-by-product. Accessed 21 Dec 2017. UR - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/public-summary-documents-by-product ID - ref44 ER - TY - STD TI - PHARMAC Pharmaceutical Management Agency. Application Tracker. http://www.pharmac.govt.nz/patients/ApplicationTracker. Accessed 21 Dec 2017. UR - http://www.pharmac.govt.nz/patients/ApplicationTracker ID - ref45 ER - TY - STD TI - INESSS: Drug products undergoing evaluation and evaluated: https://www.inesss.qc.ca/en/activities/drug-products/drug-products-undergoing-evaluation-and-evaluated.html. Accessed 21 Dec 2017. UR - https://www.inesss.qc.ca/en/activities/drug-products/drug-products-undergoing-evaluation-and-evaluated.html ID - ref46 ER - TY - STD TI - Régie de l'assurance maladie du Québec. List of Medications : http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/liste_med/liste_med_2017_03_22_en.pdf. Accessed 21 Dec 2017. UR - http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/liste_med/liste_med_2017_03_22_en.pdf ID - ref47 ER - TY - BOOK AU - Altman, D. G. PY - 1991 DA - 1991// TI - Practical statistics for medical research PB - Chapman and Hall CY - London ID - Altman1991 ER - TY - JOUR AU - Janoudi, G. AU - Amegatse, W. AU - McIntosh, B. AU - Sehgal, C. AU - Richter, T. PY - 2016 DA - 2016// TI - Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH Common Drug Review JO - Orphanet J Rare Dis VL - 11 UR - https://doi.org/10.1186/s13023-016-0539-3 DO - 10.1186/s13023-016-0539-3 ID - Janoudi2016 ER - TY - JOUR AU - Dupont, A. G. AU - Van Wilder, P. B. PY - 2011 DA - 2011// TI - Access to orphan drugs despite poor quality of clinical evidence JO - Br J Clin Pharmacol VL - 71 UR - https://doi.org/10.1111/j.1365-2125.2010.03877.x DO - 10.1111/j.1365-2125.2010.03877.x ID - Dupont2011 ER - TY - JOUR AU - Rawson, N. S. B. PY - 2017 DA - 2017// TI - Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost JO - Orphanet J Rare Dis VL - 12 UR - https://doi.org/10.1186/s13023-017-0611-7 DO - 10.1186/s13023-017-0611-7 ID - Rawson2017 ER - TY - JOUR AU - Liden, D. AU - Jaksa, A. AU - Daniel, K. AU - Ho, Y. PY - 2014 DA - 2014// TI - CADTH recommendations as predictors for drug availability in British Columbia and Ontario JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.03.040 DO - 10.1016/j.jval.2014.03.040 ID - Liden2014 ER - TY - JOUR AU - Allen, N. AU - Walker, S. R. AU - Liberti, L. AU - Sehgal, C. AU - Salek, M. S. PY - 2016 DA - 2016// TI - Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study JO - CMAJ Open VL - 4 UR - https://doi.org/10.9778/cmajo.20160006 DO - 10.9778/cmajo.20160006 ID - Allen2016 ER - TY - JOUR AU - Menon, D. AU - Clark, D. AU - Stafinski, T. PY - 2015 DA - 2015// TI - Reimbursement of drugs for rare diseases through the public healthcare system in Canada: where are we now? JO - Healthc Policy VL - 11 ID - Menon2015 ER - TY - JOUR AU - Lexchin, J. AU - Mintzes, B. PY - 2008 DA - 2008// TI - Medicine reimbursement recommendations in Canada, Australia and Scotland JO - Am J Manag Care VL - 14 ID - Lexchin2008 ER - TY - JOUR AU - Allen, N. AU - Walker, S. R. AU - Liberti, L. AU - Salek, S. PY - 2017 DA - 2017// TI - Health technology assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England and Scotland JO - Value Health VL - 20 UR - https://doi.org/10.1016/j.jval.2016.10.014 DO - 10.1016/j.jval.2016.10.014 ID - Allen2017 ER - TY - JOUR AU - Adkins, E. M. AU - Nicholson, L. AU - Floyd, D. AU - Ratcliffe, M. AU - Chevrou-Severac, H. PY - 2017 DA - 2017// TI - Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? JO - Clinicoecon Outcomes Res VL - 9 UR - https://doi.org/10.2147/CEOR.S134230 DO - 10.2147/CEOR.S134230 ID - Adkins2017 ER - TY - JOUR AU - Mills, F. AU - Poinas, A. C. AU - Siu, E. AU - Wyatt, G. PY - 2014 DA - 2014// TI - Consistency in reimbursement decisions at Canadian HTA agencies: INESSS versus CDR JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.03.172 DO - 10.1016/j.jval.2014.03.172 ID - Mills2014 ER -